[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349532-105":59,"doc-detail-349532-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cross-cancer-detectability-of-ctdna-biomarkers-in-asian-populations-implications-for-pan-cancer-detection","Cross-Cancer Detectability of ctDNA Biomarkers in Asian Populations - Implications for Pan-Cancer Detection","","Cancer management relies on earlier detection to improve patient outcomes, and circulating tumor DNA (ctDNA) enables minimally invasive liquid biopsies for cancer detection and monitoring. This review maps ctDNA-detected gene biomarkers across cancer types in Asian populations and identifies genomic alteration patterns relevant to pan-cancer detection. Following PRISMA 2020, PubMed studies were searched and data extracted at the gene-event level. Across 100 studies, 113 ctDNA biomarkers spanning 23 cancer types were synthesized, showing mutation heterogeneity and broader cross-cancer amplification events.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cross-cancer-detectability-of-ctdna-biomarkers-in-asian-populations-implications-for-pan-cancer-detection/349532/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cross-cancer-detectability-of-ctdna-biomarkers-in-asian-populations-implications-for-pan-cancer-detection/349532.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the review?","Question",{"text":112,"@type":113},"The review mapped ctDNA-detected gene biomarkers across cancer types in Asian populations and identified genomic alteration patterns with potential relevance for pan-cancer detection.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were studies selected and data extracted?",{"text":117,"@type":113},"Studies were identified by systematically searching PubMed for tumor-specific ctDNA in Asian cancer populations under PRISMA 2020, then data were extracted at the gene-event level treating each reported alteration as an independent evidence entry.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about mutation-based versus amplification-based biomarkers?",{"text":121,"@type":113},"Mutation events were most commonly reported but were highly heterogeneous and largely cancer-specific. In contrast, gene amplification events—especially involving ERBB2, MET, and MYC—appeared across multiple cancer entities and showed broader cross-cancer distribution.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349532,1790472337,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Management and Research  \nOpen Access Full Text Article REVIEW  \nCross-Cancer Detectability of ctDNA Biomarkers in Asian Populations: Implications for Pan-Cancer Detection  \nAura Rindu Rarasati 1 , Julia Ramadhanti 2 , 3 , Ilma Fauziah Ma’ruf4 , Enny Rohmawaty 2 , 3 , Muhammad Hasan Bashari 2 , 3 , Hesti Lina Wiraswati 2 , 3  \n1Faculty of Medicine, Universitas Padjadjaran, Sumedang, West Java, Indonesia; 2Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Sumedang, West Java, Indonesia; 3Oncology and Stem Cell Working Group, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia; 4Research Center for Pharmaceutical Ingredients and Traditional Medicine, National Research and Innovation Agency, Bogor, West Java, Indonesia  \nCorrespondence: Hesti Lina Wiraswati, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Sumedang, West Java, 45363, Indonesia, Tel +22 84288888, Email [hesti.lina@unpad.ac.id](hesti.lina@unpad.ac.id)  \n\n| Background: Cancer remains a leading cause of global mortality, making early detection essential for improvingpatient outcomes. Circulating tumor DNA (ctDNA) has emerged as a minimally invasive liquid biopsy approach for cancer detection and monitoring. Nevertheless, current ctDNA research is dominated by mutation-based analyses, which tend to be highly heterogeneous across cancer types and may therefore limit their usefulness for pan-cancer detection.\u003Cbr>Objective: This review aimed to map ctDNA-detected gene biomarkers across cancer types in Asian populations and to identify genomic alteration patterns with potential relevance for pan-cancer detection.\u003Cbr>Methods: Following the PRISMA 2020 guidelines, PubMed was systematically searched for studies investigating tumor-specific ctDNA in Asian cancer populations. Data were extracted at the gene-event level, treating each reported genomic alteration as an independent evidence entry. Genes, alteration types, and associated cancer types were synthesize using a descriptive frequency-based evidence mapping approach. Reported clinical relevance was also summarized to provide clinical context for the identified biomarkers. Results: A total of 100 studies identified 113 ctDNA biomarkers across 23 cancer types, with lung, colorectal, and breast cancers being the most frequently investigated. Mutation events were the most commonly reported, reflecting the dominance of mutationfocused ctDNA assays. However, mutation profiles were highly heterogeneous and largely cancer-specific. In contrast, gene amplification events, particularly involving ERBB2, MET, and MYC, were reported across multiple cancer entities and demonstrated broader cross-cancer distribution, suggesting shared oncogenic mechanisms rather than lineage-specific events.\u003Cbr>Conclusion: This descriptive evidence mapping suggests that the potential relevance of ctDNA biomarkers in Asian populations may depend more on the type of genomic alteration than on gene-reporting frequency alone. Mutation-based ctDNA biomarkers were predominantly associated with tumor-specific applications, whereas amplification-based alterations were observed across multiple cancer types. These findings provide a framework for future biomarker prioritization for cancer detection and require validation through studies evaluating clinical performance and prospective implementation.\u003Cbr>Keywords: circulating tumor DNA, ctDNA, liquid biopsy, biomarkers, pan-cancer detection, gene amplification |\n| --- |\n| Introduction\u003Cbr>Cancer, or neoplasia, refers to a broad range of diseases characterized by the uncontrolled proliferation of abnormal cells with the capacity to invade surrounding cells and metastasize to other organs or tissues. This biological behaviour makes cancer a major contributor to global mortality.1 According to data from the World Health Organization (WHO) 2024, approximately 20 million new cases of cancer were detected globally in the past y","cbCaivM3R5Tanho0","https://ap.wps.com/l/cbCaivM3R5Tanho0","pdf",5161493,"English","# Background\n## Objective\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the main goal of the review?\",\"answer\":\"The review mapped ctDNA-detected gene biomarkers across cancer types in Asian populations and identified genomic alteration patterns with potential relevance for pan-cancer detection.\"},{\"question\":\"How were studies selected and data extracted?\",\"answer\":\"Studies were identified by systematically searching PubMed for tumor-specific ctDNA in Asian cancer populations under PRISMA 2020, then data were extracted at the gene-event level treating each reported alteration as an independent evidence entry.\"},{\"question\":\"What did the results show about mutation-based versus amplification-based biomarkers?\",\"answer\":\"Mutation events were most commonly reported but were highly heterogeneous and largely cancer-specific. In contrast, gene amplification events—especially involving ERBB2, MET, and MYC—appeared across multiple cancer entities and showed broader cross-cancer distribution.\"}]","Cross-Cancer Detectability of ctDNA Biomarkers in Asian Populations - Implications for Pan-Cancer Detection | PDF",1790084220,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/354ac50b797e78fc75ea98edc7046c08.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/402f8cbb2fa3be5c99137d4566794f5f.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ab728d037a87fd9bf5e706a21362767.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87ee9754cfa87f1648c029361534e8be.webp",980,1268]